Linda, my fair lady, yes it did...
From the text of your post today:
<<<On January 15, 1998, a press release was issued by a market
analyst concerning Zonagen and Vasomax entitled "Zonagen's
Fast-Acting Claims Proven False and Fraudulent." The press release
revealed that review of Zonagen's patent application demonstrates
that Vasomax contains "nothing secret or new" and that Vasomax "is
by every measure much slower acting than standard phentolamine,"
citing prior scientific research.
In response, the price of Zonagen common stock fell 11%, from
$19.00 per share to $16.93 per share, a decline of 61% from a Class
Period high of $44.125 per share reached on October 13, 1997.>>>
Who do you think they're referring to, if not Asensio?? The humorous thing to watch will be what happens when the second patent issues & the NDA is filed. What are they going to sue over - a development stage biotech firm was later than expected in filing their NDA?? This is a disappointment & probably had something to do with the stock performance - but something to warrant a legal judgement - I don't think so.
This stock has been under relentless attack from various sides since November. I think it was about $33 when the first bogus report was issued - dropped to what? - $14 & now back to $22 & holding. Maybe it's time someone started to examine the reasons why it has held up so well, instead of baseless opinions and attacks.
As always, just MHO. |
